David D Bushart1,2, Haoran Huang1, Luke J Man1, Logan M Morrison1,3, Vikram G Shakkottai1,4. 1. Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA. 2. Ohio State University College of Medicine, Columbus, Ohio, USA. 3. Neuroscience Graduate Program, University of Michigan, Ann Arbor, Michigan, USA. 4. Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan, USA.
Abstract
BACKGROUND: A combination of central muscle relaxants, chlorzoxazone and baclofen (chlorzoxazone-baclofen), has been proposed for treatment of cerebellar symptoms in human spinocerebellar ataxia. However, central muscle relaxants can worsen balance. The optimal dose for target engagement without toxicity remains unknown. Using the genetically precise Atxn1154Q/2Q model of spinocerebellar ataxia type 1, we aimed to determine the role of cerebellar dysfunction in motor impairment. We also aimed to identify appropriate concentrations of chlorzoxazone-baclofen needed for target engagement without toxicity to plan for human clinical trials. METHODS: We use patch clamp electrophysiology in acute cerebellar slices and immunostaining to identify the specific ion channels targeted by chlorzoxazone-baclofen. Behavioral assays for coordination and grip strength are used to determine specificity of chlorzoxazone-baclofen for improving cerebellar dysfunction without off-target effects in Atxn1154Q/2Q mice. RESULTS: We identify irregular Purkinje neuron firing in association with reduced expression of ion channels Kcnma1 and Cacna1g in Atxn1154Q/2Q mice. Using in vitro electrophysiology in brain slices, we identified concentrations of chlorzoxazone-baclofen that improve Purkinje neuron spike regularity without reducing firing frequency. At a disease stage in Atxn1154Q/2Q mice when motor impairment is due to cerebellar dysfunction, orally administered chlorzoxazone-baclofen improves motor performance without affecting muscle strength. CONCLUSION: We identify a tight relationship between baclofen-chlorzoxazone concentrations needed to engage target and levels above which cerebellar function will be compromised. We propose to use this information for a novel clinical trial design, using sequential dose escalation within each subject, to identify dose levels that are likely to improve ataxia symptoms while minimizing toxicity.
BACKGROUND: A combination of central muscle relaxants, chlorzoxazone and baclofen (chlorzoxazone-baclofen), has been proposed for treatment of cerebellar symptoms in human spinocerebellar ataxia. However, central muscle relaxants can worsen balance. The optimal dose for target engagement without toxicity remains unknown. Using the genetically precise Atxn1154Q/2Q model of spinocerebellar ataxia type 1, we aimed to determine the role of cerebellar dysfunction in motor impairment. We also aimed to identify appropriate concentrations of chlorzoxazone-baclofen needed for target engagement without toxicity to plan for human clinical trials. METHODS: We use patch clamp electrophysiology in acute cerebellar slices and immunostaining to identify the specific ion channels targeted by chlorzoxazone-baclofen. Behavioral assays for coordination and grip strength are used to determine specificity of chlorzoxazone-baclofen for improving cerebellar dysfunction without off-target effects in Atxn1154Q/2Q mice. RESULTS: We identify irregular Purkinje neuron firing in association with reduced expression of ion channels Kcnma1 and Cacna1g in Atxn1154Q/2Q mice. Using in vitro electrophysiology in brain slices, we identified concentrations of chlorzoxazone-baclofen that improve Purkinje neuron spike regularity without reducing firing frequency. At a disease stage in Atxn1154Q/2Q mice when motor impairment is due to cerebellar dysfunction, orally administered chlorzoxazone-baclofen improves motor performance without affecting muscle strength. CONCLUSION: We identify a tight relationship between baclofen-chlorzoxazone concentrations needed to engage target and levels above which cerebellar function will be compromised. We propose to use this information for a novel clinical trial design, using sequential dose escalation within each subject, to identify dose levels that are likely to improve ataxia symptoms while minimizing toxicity.
Authors: T Schmitz-Hübsch; R Fimmers; M Rakowicz; R Rola; E Zdzienicka; R Fancellu; C Mariotti; C Linnemann; L Schöls; D Timmann; A Filla; E Salvatore; J Infante; P Giunti; R Labrum; B Kremer; B P C van de Warrenburg; L Baliko; B Melegh; C Depondt; J Schulz; S Tezenas du Montcel; T Klockgether Journal: Neurology Date: 2010-02-23 Impact factor: 9.910
Authors: Ravi Chopra; Aaron H Wasserman; Stefan M Pulst; Chris I De Zeeuw; Vikram G Shakkottai Journal: Hum Mol Genet Date: 2018-04-15 Impact factor: 6.150
Authors: Guiling Zhao; Zachary P Neeb; M Dennis Leo; Judith Pachuau; Adebowale Adebiyi; Kunfu Ouyang; Ju Chen; Jonathan H Jaggar Journal: J Gen Physiol Date: 2010-08-16 Impact factor: 4.086
Authors: Tetsuo Ashizawa; Karla P Figueroa; Susan L Perlman; Christopher M Gomez; George R Wilmot; Jeremy D Schmahmann; Sarah H Ying; Theresa A Zesiewicz; Henry L Paulson; Vikram G Shakkottai; Khalaf O Bushara; Sheng-Han Kuo; Michael D Geschwind; Guangbin Xia; Pietro Mazzoni; Jeffrey P Krischer; David Cuthbertson; Amy Roberts Holbert; John H Ferguson; Stefan M Pulst; S H Subramony Journal: Orphanet J Rare Dis Date: 2013-11-13 Impact factor: 4.123
Authors: James P Orengo; Meike E van der Heijden; Shuang Hao; Jianrong Tang; Harry T Orr; Huda Y Zoghbi Journal: Dis Model Mech Date: 2018-02-26 Impact factor: 5.758
Authors: Jan Cendelin; Marija Cvetanovic; Mandi Gandelman; Hirokazu Hirai; Harry T Orr; Stefan M Pulst; Michael Strupp; Filip Tichanek; Jan Tuma; Mario Manto Journal: Cerebellum Date: 2021-08-10 Impact factor: 3.648
Authors: Sharan R Srinivasan; Haoran Huang; Wei-Chih Chang; Joshua A Nasburg; Hai M Nguyen; Tim Strassmaier; Heike Wulff; Vikram G Shakkottai Journal: Mol Pharmacol Date: 2022-04-30 Impact factor: 4.054
Authors: Ravi Chopra; David D Bushart; John P Cooper; Dhananjay Yellajoshyula; Logan M Morrison; Haoran Huang; Hillary P Handler; Luke J Man; Warunee Dansithong; Daniel R Scoles; Stefan M Pulst; Harry T Orr; Vikram G Shakkottai Journal: Hum Mol Genet Date: 2020-11-25 Impact factor: 6.150